20945-53-3

Basic information

• Product Name: L-N-CBZ-3-PYRAZOL-1-YL-ALANINE
• Synonyms: L-N-CBZ-3-PYRAZOL-1-YL-ALANINE;(S)-2-[(Benzyloxycarbonyl)amino]-3-(1H-pyrazol-1-yl)propanoic acid;N-Cbz-3-(Pyrazol-1-yl)-L-alanine;Z-3-(Pyrazol-1-yl)-L-Ala-OH
• CAS NO: 20945-53-3
• Molecular Formula: C₁₄H₁₅N₃O₄
• Molecular Weight: 289.29
• Mol File: 20945-53-3.mol
• Article Data: 28

Chemical Properties

• Boiling Point: 533.1±50.0 °C(Predicted)
• Appearance: /
• Density: 1.31
• PKA: 3.49±0.10(Predicted)
• CAS DataBase Reference: L-N-CBZ-3-PYRAZOL-1-YL-ALANINE(CAS DataBase Reference)
• NIST Chemistry Reference: L-N-CBZ-3-PYRAZOL-1-YL-ALANINE(20945-53-3)
• EPA Substance Registry System: L-N-CBZ-3-PYRAZOL-1-YL-ALANINE(20945-53-3)

Safety Data

• Hazardous Substances Data: 20945-53-3(Hazardous Substances Data)

Usage

General Description

L-N-CBZ-3-PYRAZOL-1-YL-ALANINE is a chemical compound that is often used in the field of pharmaceuticals and medicine. It is a derivative of alanine, an amino acid that is essential for protein synthesis in the human body. The L-N-CBZ-3-PYRAZOL-1-YL-ALANINE compound contains a pyrazole ring, which gives it unique structural and functional properties. It is commonly used as a building block in the synthesis of various pharmaceutical drugs and research compounds. The compound is also involved in the study of protein structure and function, as well as in drug development and discovery processes. Its specific characteristics and properties make it an important molecule in the field of biochemistry and medicinal chemistry.

Upstream product

• 172749-95-0 (S)-benzyl 2-oxooxetan-3-ylcarbamate 
• 288-13-1 NH-pyrazole 
• 26054-60-4 ((S)-2-Oxo-oxetan-3-yl)-carbamic acid benzyl ester 

Downstream Products

• 149269-90-9 (S)-α-amino-N-[(1S,2R,3S)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]-3-(pyrazol-1-yl)propionamide 

Relevant articles and documents

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.